Cyclacel Pharmaceuticals Inc. Stock
With 12 Sell predictions and only 2 Buy predictions the community sentiment for Cyclacel Pharmaceuticals Inc. is rather negative.
On the other hand, the target price of 14 € is above the current price of 0.22 € for Cyclacel Pharmaceuticals Inc., so the potential is actually 6263.64%.
Our community identified positive and negative aspects for Cyclacel Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "EBIT Margin" as a plus for the Cyclacel Pharmaceuticals Inc. stock. On the other hand our users think that "Expected Cash Flow" could be a problem in the future.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
Vaxart Inc. | 0.200% | -3.097% | 24.939% | -31.194% | 48.662% | -85.894% | - |
Larimar Therapeutics Inc. | 3.130% | -14.094% | 7.563% | 84.971% | 56.863% | -4.478% | -77.179% |
Qualigen Therapeutics Inc. | -1.420% | -2.190% | -6.944% | -70.710% | -46.507% | -98.285% | - |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its price target lowered by analysts at Roth Mkm from $21.00 to $11.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat